x

Viracta Therapeutics, Inc. (Nasdaq:VIRX)

Health Care/Life Sciences • Biotechnology
CIK 1061027
Company

Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is headquartered in Cardiff, CA.

Address
2533 South Coast Highway 101
Suite 210
Cardiff, California 92007
Employees
32
Stock Info
Close
$0.9446
Day Range
0.9101 - 0.9800
52 Week Range
0.4300 - 2.3800
Average volume
153.1K
Short Interest
678.82K (02/15/24)
% of Float Shorted
2.53%
Market Cap
$36.31M
Revenue
N/A
Net Income
-$49.2M
2020 Sales Growth
N/A
Rev. per Employee
N/A
P/E Ratio
N/A
EPS
-$1.2341
Yield
N/A
Dividend
N/A
Ex-Dividend Date
N/A
Key Executives
Board Of Directors
President, Chief Executive Officer & Director
Mark A Rothera MBA
Director
Ivor Royston MD
Chairman
Roger James Pomerantz MD
Independent Director
Thomas E Darcy CPA
Independent Director
Sam Murphy PhD
Independent Director
Barry J Simon MD
Independent Director
Stephen Rubino PhD, MBA
Independent Director
Jane Chung
Independent Director
Flavia Borellini PhD
Independent Director
Jane F Barlow MD, MBA
SEC filings
DateFormEvent
29 Nov, 2024 8-K
27 Nov, 2024 4
27 Nov, 2024 4
22 Nov, 2024 8-K
14 Nov, 2024 SC 13G/A
13 Nov, 2024 8-K
13 Nov, 2024 10-Q
6 Nov, 2024 8-K
12 Sep, 2024 4
12 Sep, 2024 4
14 Aug, 2024 10-Q
14 Aug, 2024 8-K
29 Jul, 2024 8-K
24 Jun, 2024 4
24 Jun, 2024 4
24 Jun, 2024 4
24 Jun, 2024 4
24 Jun, 2024 4
24 Jun, 2024 4
24 Jun, 2024 4
24 Jun, 2024 4
24 Jun, 2024 4
20 Jun, 2024 8-K
31 May, 2024 8-K
29 May, 2024 4
29 May, 2024 4
16 May, 2024 3
16 May, 2024 4
14 May, 2024 8-K
9 May, 2024 8-K
9 May, 2024 10-Q
26 Apr, 2024 ARS
26 Apr, 2024 DEFA14A
26 Apr, 2024 DEF 14A
9 Apr, 2024 8-K
22 Mar, 2024 3
20 Mar, 2024 8-K
13 Mar, 2024 4
13 Mar, 2024 4
13 Mar, 2024 4
7 Mar, 2024 10-K
7 Mar, 2024 S-8
7 Mar, 2024 8-K
27 Feb, 2024 144
27 Feb, 2024 4
27 Feb, 2024 4
27 Feb, 2024 4
13 Feb, 2024 SC 13G
4 Dec, 2023 4
28 Nov, 2023 4
28 Nov, 2023 4
28 Nov, 2023 4
17 Nov, 2023 8-K
9 Nov, 2023 8-K
9 Nov, 2023 10-Q
4 Oct, 2023 8-K
29 Aug, 2023 4
29 Aug, 2023 4
29 Aug, 2023 4
18 Aug, 2023 4
18 Aug, 2023 4
16 Aug, 2023 3
14 Aug, 2023 8-K
14 Aug, 2023 10-Q
7 Aug, 2023 8-K
9 Jun, 2023 4
9 Jun, 2023 4
9 Jun, 2023 4
9 Jun, 2023 4
9 Jun, 2023 4
9 Jun, 2023 4
9 Jun, 2023 8-K
9 Jun, 2023 4
9 Jun, 2023 4
9 Jun, 2023 4
26 May, 2023 4
26 May, 2023 4
26 May, 2023 4
26 May, 2023 144
9 May, 2023 10-Q
8 May, 2023 8-K
5 May, 2023 8-K/A
2 May, 2023 8-K
27 Apr, 2023 DEF 14A
27 Apr, 2023 DEFA14A
27 Apr, 2023 ARS
31 Mar, 2023 8-K
17 Mar, 2023 4
17 Mar, 2023 4
17 Mar, 2023 4
14 Mar, 2023 10-K
14 Mar, 2023 S-8
13 Mar, 2023 8-K
28 Feb, 2023 4
28 Feb, 2023 4
28 Feb, 2023 4
28 Feb, 2023 4
14 Feb, 2023 SC 13G/A
10 Jan, 2023 SC 13D/A
29 Nov, 2022 4
29 Nov, 2022 4
29 Nov, 2022 4
29 Nov, 2022 4
10 Nov, 2022 8-K
10 Nov, 2022 10-Q
19 Sep, 2022 3
19 Sep, 2022 8-K CEO Change
19 Sep, 2022 4
29 Aug, 2022 4
29 Aug, 2022 4
29 Aug, 2022 4
29 Aug, 2022 4
26 Aug, 2022 8-K
11 Aug, 2022 4
11 Aug, 2022 8-K
11 Aug, 2022 4
11 Aug, 2022 3
9 Aug, 2022 10-Q
9 Aug, 2022 8-K
8 Jul, 2022 SC 13G
27 Jun, 2022 S-8
10 Jun, 2022 4
10 Jun, 2022 4
10 Jun, 2022 4
10 Jun, 2022 4
10 Jun, 2022 4
10 Jun, 2022 4
10 Jun, 2022 4
10 Jun, 2022 4
10 Jun, 2022 4
8 Jun, 2022 8-K
27 May, 2022 4
27 May, 2022 4
27 May, 2022 4
27 May, 2022 4
10 May, 2022 10-Q
10 May, 2022 8-K
27 Apr, 2022 8-K
27 Apr, 2022 DEFA14A
27 Apr, 2022 DEF 14A
15 Apr, 2022 8-K
18 Mar, 2022 4
18 Mar, 2022 S-8
18 Mar, 2022 4
18 Mar, 2022 4
17 Mar, 2022 10-K
16 Mar, 2022 8-K
1 Mar, 2022 4
1 Mar, 2022 4
1 Mar, 2022 4
1 Mar, 2022 4
15 Feb, 2022 SC 13G/A
14 Feb, 2022 SC 13G
14 Feb, 2022 SC 13G/A
9 Feb, 2022 SC 13G/A
4 Feb, 2022 SC 13G
30 Dec, 2021 4
1 Dec, 2021 144
1 Dec, 2021 144
1 Dec, 2021 144
29 Nov, 2021 4
29 Nov, 2021 4
29 Nov, 2021 4
29 Nov, 2021 4
15 Nov, 2021 4
10 Nov, 2021 8-K
10 Nov, 2021 10-Q
5 Nov, 2021 8-K
6 Oct, 2021 8-K
29 Sep, 2021 4
23 Aug, 2021 8-K
17 Aug, 2021 3
17 Aug, 2021 4
17 Aug, 2021 4
17 Aug, 2021 3
16 Aug, 2021 8-K
12 Aug, 2021 10-Q
12 Aug, 2021 8-K
21 Jul, 2021 8-K
6 Jul, 2021 8-K
4 Jun, 2021 EFFECT
2 Jun, 2021 CORRESP
2 Jun, 2021 UPLOAD
1 Jun, 2021 4
28 May, 2021 8-K
28 May, 2021 S-3
13 May, 2021 10-Q
13 May, 2021 4
12 May, 2021 8-K
14 Apr, 2021 8-K
2 Apr, 2021 S-8
1 Apr, 2021 8-K
30 Mar, 2021 4
30 Mar, 2021 4
30 Mar, 2021 4
30 Mar, 2021 4
30 Mar, 2021 4
30 Mar, 2021 4
30 Mar, 2021 4
30 Mar, 2021 4
30 Mar, 2021 4
30 Mar, 2021 4
30 Mar, 2021 4
23 Mar, 2021 8-K/A
23 Mar, 2021 8-K
11 Mar, 2021 SC 13D/A
8 Mar, 2021 SC 13G
5 Mar, 2021 SC 13G/A
4 Mar, 2021 3
4 Mar, 2021 3
4 Mar, 2021 8-K
2 Mar, 2021 SC 13D
25 Feb, 2021 3
25 Feb, 2021 3
24 Feb, 2021 3
24 Feb, 2021 3
24 Feb, 2021 3
24 Feb, 2021 3
24 Feb, 2021 8-K CEO Change
24 Feb, 2021 3
24 Feb, 2021 3
24 Feb, 2021 3
24 Feb, 2021 10-K
23 Feb, 2021 8-K
16 Feb, 2021 SC 13G/A
16 Feb, 2021 425
16 Feb, 2021 SC 13G/A
16 Feb, 2021 SC 13G/A
16 Feb, 2021 SC 13G/A
16 Feb, 2021 SC 13G/A
12 Feb, 2021 425
12 Feb, 2021 8-K
11 Feb, 2021 425
14 Jan, 2021 424B3
14 Jan, 2021 EFFECT
13 Jan, 2021 S-4/A
12 Jan, 2021 CORRESP
7 Jan, 2021 3
7 Jan, 2021 SC 13G/A
7 Jan, 2021 425
4 Jan, 2021 SC 13G
29 Dec, 2020 UPLOAD
Last update:2024-03-06 13:40:17.966075
Viracta Therapeutics, Inc. by TradingView

Sign Up to Subscribe